![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Adds Chemically Synthesized Products to NDA-BLA Transition List
FDA Adds Chemically Synthesized Products to NDA-BLA Transition List
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
January 23, 2020
The FDA has updated its list of NDAs that will shift to being regulated as BLAs on March 23, adding new synthesized proteins to reflect a provision in the federal government’s fiscal 2020 budget bill.
The spending bill provision that is now law amended the definition of “biological product” to include “any chemically synthesized polypeptide[s].”
The three chemically synthesized products — Ferring’s Cushing’s syndrome treatment Acthrel (corticorelin ovine triflutate), Pfizer’s antibiotic Elase-chloromycetin (fibrinolysin and desoxyribonuclease combined [bovine] with chloramphenicol) and Sanofi’s diabetes treatment Adlyxin (lixisenatide) — are now seen as biological products.
Upcoming Events
-
21Oct